As part of a natural history study of giant axonal neuropathy, we hypothesized that the Friedreich Ataxia Rating Scale and the Gross Motor Function Measure would show a significant change over 6 months, reflecting subjects’ decline in motor function. The Friedreich Ataxia Rating Scale was performed on 11 subjects and the Gross Motor Function Measure was performed on 10 subjects twice with a six-month interval. A paired two-tailed t-test was used to assess the difference in each subject’s score. Significant changes were found over six months of 11.7 ± 11.0 (P = 0.006) for the Friedreich Ataxia Rating Scale and –10.0 ± 13.5 (P = 0.043) for the Gross Motor Function Measure, reflecting subjects’ decline in motor function on examination and by report. These standardized assessments of clinical function are the first to be validated in giant axonal neuropathy and will be used in an upcoming gene therapy clinical trial.
AkagiMMohriIIwataniY. Clinicogenetical features of a Japanese patient with giant axonal neuropathy. Brain Dev. 2012;34:156–162.
2.
RothLAJohnson-KernerBLMarraJD. The absence of curly hair is associated with a milder phenotype in giant axonal neuropathy. Neuromuscul Disord. 2014;24:48–55.
3.
BomontPIoosCYalcinkayaC. Identification of seven novel mutations in the GAN gene. Hum Mutat. 2003;21:446–451.
4.
BrunoCBertiniEFedericoA. Clinical and molecular findings in patients with giant axonal neuropathy (GAN). Neurology. 2004;62:13–16.
TazirMSoniaNLaurentM. Phenotypic variability in giant axonal neuropathy. Neuromuscul Disord. 2009;19:270–274.
7.
ZhangLPZouLP. Clinical and genetic studies in a Chinese family with giant axonal neuropathy. J Child Neurol. 2009;24:1552–1556.
8.
DemirEBomontPErdemS. Giant axonal neuropathy: clinical and genetic study in six cases. J Neurol Neurosurg Psychiatry. 2005;76:825–832.
9.
HouldenHGrovesMMiedzybrodzkaZ. New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:1267–1270.
10.
BomontPCavalierLBlondeauF. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet. 2000;26:370–374.
11.
GraySJNagabhushan KalburgiSMcCownTJJude SamulskiR. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013;20:450–459.
12.
LynchDRFarmerJMTsouAY. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006;66:1711–1716.
13.
NordmarkEHägglundGJarnloGB. Reliability of the gross motor function measure in cerebral palsy. Scand J Rehabil Med. 1997;29:25–28.
14.
JebsenRHTaylorNTrieschmannRB. An objective and standardized test of hand function. Arch Phys Med Rehabil. 1969;50:311–319.
15.
BurnsJOuvrierREstilowT. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol. 2012;71:642–652.
16.
MontesJMcDermottMMartensW. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74:833–838.
17.
KaufmannPMcDermottMPDarrasBT. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79:1889–1897.
18.
BoizotATalmat-AmarYMorroghD. The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test. Acta Neuropathol Commun. 2014;2:47–58.
19.
BuysseKVergultSMusscheS. Giant axonal neuropathy caused by compound heterozygosity of a maternally inherited microdeletion and a paternal mutation within the GAN gene. Am J Med Genet A. 2010;152A:2802–2804.
NelsonLOwensHHynanLS. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord. 2006;16:374–380.
25.
Davis SearsEChungKC. Validity and responsiveness of the Jebsen-Taylor hand function test. J Hand Surg Am. 2010;35:30–37.
26.
KoopOSchirmacherANelisE. Genotype-phenotype analysis in patients with giant axonal neuropathy (GAN). Neuromuscul Disord. 2007;17:624–630.
27.
SchmidtEPDrachmanDBWienerCM. Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Muscle Nerve. 2006;33:127–132.
28.
McDonaldCMHenricsonEKHanJJ. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41:500–510.
29.
Van der PloegATClemensPRCorzoD. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362:1396–1406.
30.
PareysonDMarchesiC. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8:654–667.
31.
ZemmouriRAzzedineHAssamiS. Charcot-Marie-Tooth 2–like presentation of an Algerian family with giant axonal neuropathy. Neuromuscul Disord. 2000;10:592–598.
32.
MercuriEMessinaSBattiniR. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord. 2006;16:93–98.
